Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2023 Sep;308(3):981-988.
doi: 10.1007/s00404-023-07057-x. Epub 2023 May 16.

Prognostic factors in undifferentiated uterine sarcoma: a subanalysis of the SARCUT study

Ronalds Macuks  1 , Yusuf Yildirim  2 , Rosanna Mancari  3   4 , Patriciu Achimas-Cadariu  5 , Thumuluru K Madhuri  6 , Eugenia Ortega  7 , Michael Mallmann  8 , Oliver Zivanovic  8 , Ignacio Zapardiel  9 ; SARCUT Study Group
Affiliations
Multicenter Study

Prognostic factors in undifferentiated uterine sarcoma: a subanalysis of the SARCUT study

Ronalds Macuks et al. Arch Gynecol Obstet. 2023 Sep.

Abstract

Purpose: The aim of this study was to analyze the prognostic factors related to the recurrence rate and overall survival of patients with undifferentiated uterine sarcoma.

Methods: An international multicenter study involving 43 international centers, the SARCUT study, collected 966 uterine sarcoma cases; among them 39 cases corresponded to undifferentiated uterine sarcoma and where included in the present subanalysis. The risk factors related to the oncological outcomes where analyzed.

Results: The median age of the patients was 63 (range 14-85) years. Seventeen (43.5%) patients presented FIGO stage I. The 5-year overall survival (OS) was 15.3% and 12-months disease-free survival (DFS) 41%. FIGO stage I was significantly associated with a better prognosis. In addition, patients who received adjuvant radiotherapy showed significant longer disease-free survival compared to those without adjuvant radiotherapy (20.5 vs. 4.0 months, respectively; p = 0.04) and longer overall survival (34.7 vs. 18.2 months, respectively; p = 0.05). Chemotherapy administration was associated with shorter DFS (HR 4.41, 95% CI 1.35-14.43, p = 0.014). Persistent disease after primary treatment (HR = 6.86, 95% CI 1.51-31.09, p = 0.012) and FIGO stage IV (HR 4.12, 95%CI 1.37-12.44, p = 0.011) showed significant worse prognosis for OS.

Conclusion: FIGO stage seems to be the most important prognostic factor in patients with undifferentiated uterine sarcoma. Adjuvant radiotherapy seems to be significantly associated also to a better disease-free and overall survival. On the contrary, the role of chemotherapy administration remains unclear since was associated to a shorted DFS.

Keywords: Risk factors; SARCUT study; Undifferentiated tumors; Uterine sarcoma.

PubMed Disclaimer

References

    1. Seagle B-LL, Sobecki-Rausch J, Strohl AE, Shilpi A, Grace A, Shahabi S (2017) Prognosis and treatment of uterine leiomyosarcoma: a National Cancer Database study. Gynecol Oncol 145(1):61–70 - PubMed
    1. Hosh M, Antar S, Nazzal A, Warda M, Gibreel A, Refky B (2016) Uterine sarcoma: analysis of 13,089 cases based on surveillance, epidemiology, and end results database. Int J Gynecol Cancer 26(6):1098–1104 - PubMed
    1. Nordal RR, Thoresen SO (1997) Uterine sarcomas in Norway 1956–1992: Incidence, survival and mortality. Eur J Cancer 33:907–911 - PubMed
    1. Toro JR, Travis LB, Wu HJ, Zhu K, Fletcher CD, Devesa SS (2006) Incidence patterns of soft tissue sarcomas, regardless of primary site, in the surveillance, epidemiology and end results program, 1978–2001: An analysis of 26,758 cases. Int J Cancer 119:2922–2930 - PubMed
    1. Abeler VM, Royne O, Thoresen S, Danielsen HE, Nesland JM, Kristensen GB (2009) Uterine sarcomas in norway. A histopathological and prognostic survey of a total population from 1970 to 2000 including 419 patients. Histopathology 54:355–364 - PubMed

Publication types

LinkOut - more resources